[Hope for patients with rare diseases--"orphan" drugs]

Area of Science:

• Pharmacology
• Regulatory Affairs
• Public Health

Context:

• Rare diseases affect fewer than 5 in 10,000 people in the European Union.
• The development and marketing of treatments for rare diseases, known as "Orphan" medicinal products, face unique challenges.
• The European Union implemented "Orphan" medicinal products legislation in April 2000 to address these challenges.

Purpose:

• To present activities stimulating research, development, and marketing of "Orphan" medicinal products.
• To describe the EU "Orphan" medicinal products legislation, including designation and registration procedures.
• To analyze the incentives provided to the pharmaceutical industry for developing and marketing "Orphan" medicinal products.

Summary:

• The EU "Orphan" medicinal products legislation, enacted in April 2000, provides incentives across pre-authorization, registration, and post-authorization phases.
• The paper details the designation process and the inclusion of products in the Community register.
• It highlights the first twenty "Orphan" medicinal products receiving marketing authorization in the EU by April 2005 and examines their real-world availability in member states.

Impact:

• The legislation aims to foster the development of treatments for rare diseases, improving patient access.
• Analysis of product availability provides insights into the effectiveness of EU policies in ensuring access to orphan drugs.
• The study contributes to understanding the landscape of rare disease drug development and market access within the European Union.